Holen Sie sich die Stockscreener-App
37.86
1.91%
0.71
Newamsterdam Pharma Company Nv Aktie (NAMS) Neueste Nachrichten
Using fundamentals and technicals on NewAmsterdam Pharma Company N.V. Equity WarrantIPO Watch & Risk Managed Investment Signals - newser.com
Is NewAmsterdam Pharma Company N.V. Equity Warrant stock a top pick in earnings seasonProduct Launch & Real-Time Volume Analysis Alerts - newser.com
Can technical indicators confirm NewAmsterdam Pharma Company N.V. Equity Warrant’s reversalJuly 2025 Opening Moves & Fast Gaining Stock Reports - newser.com
Advanced analytics toolkit walkthrough for NewAmsterdam Pharma Company N.V. Equity WarrantPortfolio Return Report & Smart Allocation Stock Tips - newser.com
Caristo Chosen by Leading Pharma Company as Worldwide Imaging Core Lab to Measure Coronary Plaque and Inflammation (2025-10-14) - Seeking Alpha
How to track smart money flows in NewAmsterdam Pharma Company N.V. Equity WarrantPortfolio Performance Summary & Community Driven Trade Alerts - newser.com
Published on: 2025-10-14 03:09:18 - newser.com
Is NewAmsterdam Pharma Company N.V. stock a good choice for value investorsEarnings Recap Report & Weekly Watchlist for Consistent Profits - newser.com
Real time alert setup for NewAmsterdam Pharma Company N.V. Equity Warrant performanceJuly 2025 Setups & Step-by-Step Trade Execution Guides - newser.com
Can you recover from losses in NewAmsterdam Pharma Company N.V.Quarterly Risk Review & Weekly Market Pulse Alerts - newser.com
Why NewAmsterdam Pharma Company N.V. Equity Warrant stock attracts global investorsJuly 2025 Short Interest & Weekly Stock Performance Updates - newser.com
Tools to assess NewAmsterdam Pharma Company N.V.’s risk profile2025 Price Action Summary & Smart Investment Allocation Tips - newser.com
Technical analysis overview for NewAmsterdam Pharma Company N.V. Equity Warrant stockMarket Performance Summary & Accurate Trade Setup Notifications - newser.com
NewAmsterdam Pharma Company N.V. recovery potential after sell offM&A Rumor & Stock Portfolio Risk Control - newser.com
Is NewAmsterdam Pharma Company N.V. Equity Warrant forming a bottoming baseEarnings Growth Summary & Low Drawdown Investment Ideas - newser.com
Is it too late to sell NewAmsterdam Pharma Company N.V. Equity WarrantEarnings Beat & High Conviction Buy Zone Picks - newser.com
Will earnings trigger a reversal in NewAmsterdam Pharma Company N.V.Recession Risk & Fast Exit/Entry Strategy Plans - newser.com
Published on: 2025-10-13 07:22:45 - newser.com
Can NewAmsterdam Pharma Company N.V. stock resist sector downturns2025 Performance Recap & Community Trade Idea Sharing - newser.com
Published on: 2025-10-12 22:17:07 - newser.com
What Insider Transactions Reveal About Hindusthan Urban Infrastructure Limiteds OutlookReal-Time Stock Alerts & Free Powerful Profit Generation - earlytimes.in
NewAmsterdam Pharma (NASDAQ:NAMS) Hits New 12-Month HighHere's Why - MarketBeat
NewAmsterdam Pharma (NAMS) Stock Soars on Cholesterol Drug Breakthrough – What Investors Should Know - ts2.tech
NAMS Stock Surge: What Lies Ahead? - timothysykes.com
NewAmsterdam Pharma (NASDAQ:NAMS) Given "Sell (D-)" Rating at Weiss Ratings - MarketBeat
Why NewAmsterdam Pharma (NAMS) Is Up 7.5% After Late-Stage Obicetrapib Trial Optimism - Yahoo Finance
NewAmsterdam Pharma Company N.V. Equity Warrant stock trend forecastMarket Sentiment Review & Weekly High Conviction Trade Ideas - newser.com
Exit strategy if you’re trapped in NewAmsterdam Pharma Company N.V. Equity WarrantEarnings Beat & Reliable Price Breakout Signals - newser.com
Is this a good reentry point in NewAmsterdam Pharma Company N.V.Weekly Stock Analysis & Smart Investment Allocation Insights - newser.com
Custom watchlist performance reports with NewAmsterdam Pharma Company N.V.Weekly Market Report & Daily Technical Forecast Reports - newser.com
NewAmsterdam Pharma Company N.V. stock momentum explainedTrend Reversal & AI Enhanced Execution Alerts - newser.com
Topper, director at NewAmsterdam Pharma, buys $31,487 in shares By Investing.com - Investing.com Nigeria
Knights of Columbus Asset Advisors LLC Invests $595,000 in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
NewAmsterdam Pharma Hits New 52-Week High of $34.62 - Markets Mojo
NewAmsterdam Pharma Company N.V. (NAMS) Soars 5.9%: Is Further Upside Left in the Stock? - Nasdaq
NewAmsterdam Pharma (NAMS) Stock Analysis: Uncovering a Promising 25% Upside in Biotechnology - DirectorsTalk Interviews
Newamsterdam Pharma stock hits 52-week high at 31.96 USD By Investing.com - Investing.com Canada
NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price Up 8.8%Here's Why - MarketBeat
NewAmsterdam Pharma Co. Hits New 52-Week High of USD 31.81 - Markets Mojo
Is NewAmsterdam Pharma Company NV a good long term investmentRSI Overbought/Oversold & Exceptional Profit Trading - earlytimes.in
Newamsterdam Pharma stock hits 52-week high at 31.96 USD - Investing.com
Will NewAmsterdam Pharma Company N.V. (KH6) stock beat Nasdaq index returnsQuarterly Earnings Summary & Target Return Focused Stock Picks - newser.com
Institutional scanner results for NewAmsterdam Pharma Company N.V.Portfolio Risk Report & Entry Point Confirmation Alerts - newser.com
How NewAmsterdam Pharma Company N.V. stock performs in weak economyWeekly Stock Summary & Smart Money Movement Alerts - newser.com
Published on: 2025-10-05 03:30:23 - newser.com
NewAmsterdam Pharma Company N.V. Equity Warrant stock retracement – recovery analysisStock Surge & Real-Time Market Sentiment Alerts - newser.com
NewAmsterdam Pharma Co. NV Hits New 52-Week High at $29.66 - Markets Mojo
Exit strategy if you’re trapped in NewAmsterdam Pharma Company N.V.July 2025 Setups & Verified Technical Signals - newser.com
How NewAmsterdam Pharma Company N.V. (KH6) stock moves on employment dataJuly 2025 Volume & Free Technical Confirmation Trade Alerts - newser.com
Published on: 2025-10-02 23:50:02 - newser.com
Using data tools to time your NewAmsterdam Pharma Company N.V. exitEarnings Growth Report & Risk Adjusted Buy/Sell Alerts - newser.com
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):